Increased Serum Lipoprotein(a) Concentrations and Low Molecular Weight Phenotypes of Apolipoprotein(a) Are Associated with Symptomatic Peripheral Arterial Disease
- 1 July 2007
- journal article
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 53 (7) , 1298-1305
- https://doi.org/10.1373/clinchem.2007.088013
Abstract
Background: Increased concentrations of lipoprotein(a) [Lp(a)] have been considered a genetically determined risk factor for coronary artery and cerebrovascular disease. Only 2 small and conflicting studies have investigated the possibility of an association of peripheral arterial disease (PAD) with high serum Lp(a) concentrations and low molecular weight (LMW) phenotypes of apolipoprotein(a) [apo(a)].Methods: We measured serum concentrations of Lp(a) and apo(a) phenotypes in 213 patients with symptomatic PAD and 213 controls matched for sex, age (within 2 years), and presence of diabetes.Results: Patients with PAD showed significantly higher median serum concentrations of Lp(a) (76 vs 47 mg/L; P = 0.003) and a higher frequency of LMW apo(a) phenotypes (41% vs 26%; P = 0.002) than controls. After adjustment for several potential confounders, increased Lp(a) concentrations (>195 mg/L, i.e., 75th percentile of the entire study sample) and LMW apo(a) phenotypes were significant predictors of PAD, with odds ratios of 3.73 (95% CI 2.08–6.67; P <0.001) and 2.21 (95% CI 1.33–3.67; P = 0.002), respectively.Conclusions: In this study sample, both increased serum concentrations of Lp(a) and the presence of LMW apo(a) phenotypes were associated with the presence of symptomatic PAD independent of traditional and nontraditional cardiovascular risk factors. Because PAD is considered an indicator of systemic atherosclerotic disease, our results suggest a possible role of Lp(a) as a genetically determined marker for systemic atherosclerosis.Keywords
Funding Information
- Austrian Nationalbank (9331)
- Austrian Heart Fund
This publication has 40 references indexed in Scilit:
- Increased Pregnancy-Associated Plasma Protein-A as a Marker for Peripheral Atherosclerosis: Results from the Linz Peripheral Arterial Disease StudyClinical Chemistry, 2006
- Pregnancy-Associated Plasma Protein-A: Do Specific Markers of Vascular or Plaque Activation Exist, and Do We Really Need Them?Clinical Chemistry, 2006
- Oxidized Phospholipids, Lp(a) Lipoprotein, and Coronary Artery DiseaseNew England Journal of Medicine, 2005
- High-level lipoprotein [a] expression in transgenic mice: evidence for oxidized phospholipids in lipoprotein [a] but not in low density lipoproteinsJournal of Lipid Research, 2005
- Apolipoprotein(a) Size and Lipoprotein(a) Concentration and Future Risk of Angina Pectoris with Evidence of Severe Coronary Atherosclerosis in Men: The Physicians’ Health StudyClinical Chemistry, 2004
- Lipoprotein(a)- and low-density lipoprotein–derived cholesterol in nephrotic syndrome: Impact on lipid-lowering therapy?Kidney International, 2004
- Small Apolipoprotein(a) Size Predicts Mortality in End-Stage Renal DiseaseCirculation, 2002
- Lipoprotein(a) binds to human platelets and attenuates plasminogen binding and activationBiochemistry, 1993
- Identification of 34 Apolipoprotein(a) Isoforms: Differential Expression of Apolipoprotein(a) Alleles between American Blacks and WhitesBiochemical and Biophysical Research Communications, 1993
- cDNA sequence of human apolipoprotein(a) is homologous to plasminogenNature, 1987